<DOC>
	<DOCNO>NCT02597257</DOCNO>
	<brief_summary>The investigator conduct randomized , Double blind , Controlled Study evaluate Efficacy safety Lidocaine Infusion Treatment Management Neuropathic pain .</brief_summary>
	<brief_title>Efficacy Safety Lidocaine Infusion Treatment Management Neuropathic Pain</brief_title>
	<detailed_description>The investigator expect pain improvement treatment 3 mg/kg lidocaine , continuously infuse normal saline 250 ml .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>postherpetic neuralgia , diabetic polyneuropathy , peripheral neuropathy NRS score &gt; 4 stable oral medication 1 month trial period volunteer inform consent pregnancy , breastfeeding , possibility pregnancy pain cause upper 3 indication hypersensitivity lidocaine local anesthetic important disease heart , kidney , liver incurable disease may affect assessment adverse effect , may interfere completion study severe conduction block history intervention may affect study Enrollment clinical trial within 30 day otherwise suitable study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Lidocaine infusion therapy</keyword>
</DOC>